Auvelity for Depression After SSRIs: How It Works and What to Know
When an SSRI Does Not Provide Enough Relief
Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications for major depressive disorder. For many people, they can be helpful. For others, however, an adequate trial of an SSRI may result in only partial improvement—or little meaningful improvement at all.
That experience can be discouraging, but an inadequate response to an SSRI does not mean that all antidepressant treatments will have the same result. Depression is biologically complex, and medications can influence different signaling systems in the brain.
One newer option is Auvelity (dextromethorphan-bupropion), an FDA-approved medication for major depressive disorder in adults. Unlike SSRIs, its effects are not primarily based on blocking serotonin reuptake.
For some adults whose depression has not improved adequately with previous antidepressant treatment, discussing a medication with a different mechanism may be reasonable. Whether Auvelity is appropriate depends on a person's diagnosis, medical history, current medications, previous treatment response, and individual safety considerations.
Why Might an SSRI Not Work?
SSRIs increase the availability of serotonin by reducing its reuptake between nerve cells. This mechanism can improve depressive symptoms for many patients, but major depressive disorder cannot be explained by serotonin alone.
Depression involves multiple interacting brain systems and can be influenced by genetics, stress, sleep, medical conditions, substance use, psychological factors, and environmental circumstances. Neurotransmitter systems involving serotonin, norepinephrine, dopamine, and glutamate may all play roles.
An inadequate response can also mean different things. Some people experience almost no improvement. Others notice that certain symptoms improve while low motivation, loss of pleasure, cognitive difficulties, fatigue, or other symptoms remain.
Before changing treatment, a clinician will generally consider whether the original diagnosis remains the best explanation for the symptoms, whether the medication trial was adequate, whether side effects limited treatment, and whether medical or psychiatric conditions may be affecting the response.
A poor response to one SSRI also does not establish that someone has treatment-resistant depression. That term has more specific clinical definitions and should be applied based on an individualized psychiatric assessment.
What Is Auvelity?
Auvelity is a prescription medication containing two components: dextromethorphan and bupropion.
The FDA initially approved Auvelity for the treatment of major depressive disorder in adults in 2022. Its mechanism differs substantially from the traditional serotonin-centered model of SSRIs.
Dextromethorphan acts in part as an NMDA receptor antagonist and sigma-1 receptor agonist, influencing signaling associated with glutamate, an important neurotransmitter involved in communication and plasticity within the brain.
Bupropion has effects involving norepinephrine and dopamine and also inhibits an enzyme called CYP2D6. In Auvelity, this enzyme inhibition helps maintain dextromethorphan exposure in the body long enough to produce its intended therapeutic effects.
The combination therefore should not be thought of simply as "bupropion plus another antidepressant." Its pharmacology is distinct from SSRIs and involves several neurotransmitter pathways.
Why Auvelity May Come Up After an Unsuccessful SSRI Trial
When an antidepressant has not produced an adequate response, psychiatrists have several possible strategies. Depending on the clinical situation, these may include switching medications, adding another treatment, using psychotherapy, addressing contributing medical or sleep conditions, or considering other evidence-based interventions.
Auvelity adds another medication option because it acts differently from SSRIs.
This distinction can be particularly relevant when someone has already had an adequate trial of a serotonin-based antidepressant without sufficient benefit. A different mechanism does not guarantee a better response, but it gives the prescribing clinician another therapeutic approach to consider.
Importantly, Auvelity is FDA-approved for major depressive disorder in adults; its approval is not limited only to people who have previously failed an SSRI.
How Quickly Can Auvelity Work?
One feature that has received attention is the timing of symptom improvement observed in clinical trials.
In the Phase 3 GEMINI trial, adults with major depressive disorder were randomly assigned to dextromethorphan-bupropion or placebo for six weeks. Researchers found a statistically significant difference in depressive symptoms beginning at week one, with the difference maintained through the six-week study.
At week six, remission and response rates were also higher in the dextromethorphan-bupropion group than in the placebo group.
These results are encouraging, but they should not be interpreted as a promise that Auvelity will work within a particular number of days for an individual patient. Clinical-trial averages describe groups of participants. Individual responses can differ considerably.
Treatment still requires appropriate follow-up to evaluate effectiveness, tolerability, mood changes, and safety.
Does Research Specifically Support Auvelity After SSRIs Fail?
There is an important distinction here.
Clinical research supports dextromethorphan-bupropion as an effective treatment for adults with major depressive disorder. Reviews of the evidence have also discussed it as a potential option when patients have not achieved remission with serotonin-targeting antidepressants.
However, patients should not interpret this evidence as showing that Auvelity will necessarily work because an SSRI did not.
The pivotal GEMINI study compared dextromethorphan-bupropion with placebo, rather than specifically enrolling only patients who had failed multiple SSRIs and comparing different next-step strategies.
A separate randomized study compared dextromethorphan-bupropion with bupropion alone and also found greater improvement in depressive symptoms with the combination.
The practical takeaway is that Auvelity has evidence supporting its antidepressant effects and offers a different pharmacologic mechanism. Choosing it specifically after an unsuccessful SSRI trial remains an individualized clinical decision.
What Are the Potential Side Effects and Safety Considerations?
Like other antidepressants, Auvelity can cause side effects and is not appropriate for everyone.
According to current FDA prescribing information, common adverse reactions reported in clinical trials of adults with major depressive disorder included:
Dizziness
Headache
Diarrhea
Sleepiness
Dry mouth
Increased sweating
Sexual dysfunction
Auvelity also carries important warnings and contraindications. The current FDA labeling includes considerations involving seizure risk, increased blood pressure, activation of mania or hypomania, neuropsychiatric reactions, angle-closure glaucoma, serotonin syndrome, pregnancy-related risk, and low sodium levels (hyponatremia).
Like antidepressants generally, it also carries a boxed warning concerning increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Auvelity is not approved for pediatric patients.
A psychiatrist should therefore review medical history, psychiatric history, and other medications before prescribing it. Screening for bipolar disorder is particularly important because antidepressant treatment can precipitate mania or hypomania in susceptible individuals.
Can Auvelity Be Taken With an SSRI?
This question requires individualized medical guidance.
The current FDA prescribing information warns that taking Auvelity with SSRIs can increase the risk of serotonin syndrome, a potentially serious reaction caused by excessive serotonergic activity.
Auvelity also contains bupropion and dextromethorphan, so clinicians need to know about any other medications containing either ingredient. Additional drug interactions can occur because of the way the medication is metabolized.
Patients should not independently add Auvelity to an SSRI, stop an SSRI abruptly, or change antidepressants based on general online information. Switching or combining psychiatric medications should be planned with a prescribing clinician who can review interactions and individual risks.
What Should You Discuss With a Psychiatrist?
When depression has not improved sufficiently with an SSRI, the most useful next step is usually a broader review rather than simply asking which medication is "stronger."
Topics worth discussing include:
- Which antidepressants have already been tried and how well they worked
- Whether previous treatment produced partial improvement
- Side effects that made previous medications difficult to tolerate
- Other prescription medications, over-the-counter products, or supplements
- Personal or family history of bipolar disorder
- Seizure history or other relevant medical conditions
- Blood pressure and cardiovascular considerations
- Alcohol or substance use
- Pregnancy or plans for pregnancy
- Psychotherapy and other non-medication treatments
- The symptoms that remain most disruptive to everyday functioning
This information can help a psychiatrist determine whether Auvelity, another medication strategy, psychotherapy, or another evidence-based treatment deserves consideration.
Evidence Spotlight
**FDA Prescribing Information:** The U.S. Food and Drug Administration identifies Auvelity as a combination of dextromethorphan and bupropion. Current prescribing information includes major depressive disorder in adults among its approved indications and details important contraindications, warnings, adverse reactions, and drug interactions.
**GEMINI Phase 3 Trial:** In a randomized, double-blind clinical trial published in *The Journal of Clinical Psychiatry*, 327 adults with major depressive disorder received dextromethorphan-bupropion or placebo. The medication group showed significantly greater improvement in depression scores at six weeks, with statistically significant separation from placebo observed as early as week one.
**Randomized Bupropion-Controlled Trial:** A separate randomized controlled study found greater improvement in depression scores with dextromethorphan-bupropion than with bupropion alone. This finding supports the concept that the combination's antidepressant effects cannot simply be attributed to bupropion.
**Systematic Review:** A systematic review of clinical trials published in *CNS Drugs* evaluated the efficacy, safety, and proposed mechanisms of dextromethorphan-bupropion in adults with major depressive disorder. The review identified the medication as a clinically relevant addition to available treatment approaches while emphasizing the need to evaluate efficacy and safety within the broader evidence base.
The Bottom Line
Not improving after an SSRI can be frustrating, but it does not mean that every antidepressant approach will produce the same result.
Auvelity represents a different pharmacologic approach to major depressive disorder because its actions include NMDA and sigma-1 receptor signaling rather than relying primarily on serotonin reuptake inhibition. Clinical trials support its efficacy for major depressive disorder in adults, although no medication works for everyone.
For someone who has experienced inadequate improvement with one or more SSRIs, the important question is not simply whether Auvelity is "better." The more useful question is whether its potential benefits, risks, interactions, and mechanism make sense within that person's overall treatment history.
Individual medication decisions should be made with a qualified prescribing clinician.
Last Reviewed/Updated: 09/19/2026
Medical and Legal Disclaimer
This article is for general educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, or legal counsel. It is not a substitute for evaluation by a qualified healthcare professional. Reading this material or contacting the practice does not establish a doctor-patient relationship. Medication decisions, including starting, stopping, switching, or combining antidepressants, should be made with an appropriately licensed prescribing clinician.
Comments